GlassScriptPhysician profile
Jenna Rice
NPI 1336622463
$1,986.45
in general payments reported to CMS, 2019-2025
11 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $92.23 · 2024: $330 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,986.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $808.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $632.52 | 2024-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.81 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $97.83 | 2024 | Voquezna |
| Janssen Biotech, INC. | $73.19 | 2025 | Tremfya |
| Boston Scientific Corporation | $62.89 | 2024 | Apollo Esg System |
| Abbvie INC. | $58.64 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.27 | 2023 | Entyvio, Gattex |
| Ipsen Biopharmaceuticals, INC | $47.04 | 2025 | Iqirvo |
| Janssen Scientific Affairs, LLC | $19.90 | 2023 | Stelara |
| Ardelyx, INC. | $18.06 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Rice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.